Simcere Pharmaceutical Group Limited (HKG:2096)

Market Cap	21.78B
Revenue (ttm)	7.06B
Net Income (ttm)	780.21M
Shares Out	2.47B
EPS (ttm)	0.31
PE Ratio	28.51
Forward PE	17.44
Dividend	0.17 (1.95%)
Ex-Dividend Date	Jun 18, 2025

Volume	11,705,072
Average Volume	8,499,539
Open	8.63
Previous Close	8.74
Day's Range	8.57 - 8.97
52-Week Range	5.08 - 9.06
Beta	0.42
RSI	62.41
Earnings Date	May 8, 2025

About HKG:2096

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injecti...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 6,584
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2096

Financial Performance

In 2024, HKG:2096's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY